CHEMOENDOCRINE SCORE (CES) BASED ON PAM50 FOR BREAST CANCER WITH POSITIVE HORMONE RECEPTORS WITH AN INTERMEDIATE RISK OF RECURRENCE

摘要

This new method relates to the development of a chemoendocrine score (CES), based on the known analysis PAM50, for predicting whether a patient with breast cancer will respond to chemotherapy or to endocrine therapy, specifically in a patient with HR+/HER2- breast cancer beyond the risk of recurrence (ROR) and PAM50 intrinsic subtypes. Specifically, the clinical utility of this CES predictor is based on the intermediate PAM50 ROR group, the proportion of each CES group (sensitive to endocrine therapy, intermediate, and sensitive to chemotherapy) being greater than 25%.